NEW YORK, March 6, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation (NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE: CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Salix Pharmaceuticals Ltd. Analyst Notes
On February 25, 2014, Salix Pharmaceuticals Ltd. (Salix) announced that a New York State Supreme Court jury has issued a verdict in its favor in a lawsuit filed against the Company by Napo Pharmaceuticals relating to Fulyzaq' (crofelemer). According to Salix, the jury found that Salix was in compliance with its contractual obligations in commercializing Fulyzaq (crofelemer) in the U.S., and thus there was no breach in the license agreement between the parties. Carolyn Logan, Salix President and CEO, commented, "We are pleased with the verdict and appreciate the thoughtfulness with which the jury approached this case. Salix takes its contractual obligations to its partners very seriously. We continue to believe in the future of Fulyzaq (crofelemer) and look forward to continuing our commercialization efforts." The full analyst notes on Salix Pharmaceuticals Ltd. Are available to download free of charge at:
http://www.AnalystsReview.com/03062014/SLXP/report.pdf
--
Cerner Corporation Analyst Notes
On February 26, 2014, Cerner Corporation's (Cerner) stock increased 0.03%, ending the day at $62.18. Over the previous three trading sessions, shares of Cerner increased 0.16% compared to the Nasdaq Composite which rose 0.67% during the same period. The full analyst notes on Cerner Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03062014/CERN/report.pdf
--
Hologic Inc. Analyst Notes
On February 26, 2014, Hologic Inc.'s (Hologic) stock increased 0.46%, ending the day at $21.71. Over the previous three trading sessions, shares of Hologic declined 0.16% compared to the Nasdaq Composite which increased 0.67% during the same period. The full analyst notes on Hologic Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03062014/HOLX/report.pdf
--
Covance Inc. Analyst Notes
On February 26, 2014, Covance Inc.'s (Covance) stock increased 0.52%, ending the day at $103.42. Over the previous three trading sessions, shares of Covance increased 0.62% compared to the Dow Jones Industrial Average which advanced 0.59% during the same period. The full analyst notes on Covance Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03062014/CVD/report.pdf
--
Synta Pharmaceuticals Corp. Analyst Notes
On February 26, 2014, Synta Pharmaceuticals Corp. (Synta) announced that it will report its Q4 2013 and full year 2013 financial results on March 11, 2014, before the market opening, followed by a conference call and webcast at 10:00 a.m. ET to discuss these results and provide clinical updates. Synta stated that the live webcast can be accessed via the Investor Relations section of its website, where it will be archived. The full analyst notes on Synta Pharmaceuticals Corp. are available to download free of charge at:
http://www.AnalystsReview.com/03062014/SNTA/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
